Prelude Therapeutics (PRLD) EPS (Basic) (2019 - 2026)
Prelude Therapeutics (PRLD) posted EPS (Basic) of -$0.42 for Q1 2026, down 77.64% sequentially from -$0.23 in Q4 2025, and up 44.89% YoY from -$0.29 in Q1 2025.
Powered by 
Analysis
Prelude Therapeutics (PRLD) EPS (Basic) (2019 - 2026) Analysis & Trends
Prelude Therapeutics has reported EPS (Basic) for 8 years, with the latest figure at -$0.42 in Q1 2026.
- Quarterly EPS (Basic) rose 44.89% year-over-year to -$0.42 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.81 (up 44.73% YoY) and the FY2025 annual result came in at -$4.11, up 3.29% from the prior year.
- EPS (Basic) eased to -$0.42 in Q1 2026 per PRLD's latest filing, from -$0.23 in the prior quarter.
- Over five years, EPS (Basic) peaked at -$0.23 in Q4 2025 and troughed at -$3.05 in Q4 2022.
- A 5-year average of -$0.85 and a median of -$0.76 in 2025 frame the typical range for EPS (Basic).
- The sharpest annual moves came in 2022 and 2024: EPS (Basic) jumped 84.32% in 2022, then sank 89.52% in 2024.
- Over 5 years, EPS (Basic) stood at -$3.05 in 2022, then jumped by 79.43% to -$0.63 in 2023, then gained by 27.74% to -$0.45 in 2024, then soared by 48.17% to -$0.23 in 2025, then tumbled by 77.64% to -$0.42 in 2026.
- According to Business Quant data, EPS (Basic) over the past three periods registered -$0.42, -$0.23, and -$0.55 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.27 Bn | 131.42 Bn | 2.84 Bn | 4.34 |
| 2 | Regeneron Pharmaceuticals | 85.55 Bn | 77.56 Bn | 3.93 Bn | 12.62 |
| 3 | Argenx Se | 63.45 Bn | 58.27 Bn | 1.37 Bn | 7.70 |
| 4 | Moderna | 57.73 Bn | 52.59 Bn | 52.00 Mn | -1.96 |
| 5 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - | -3.06 |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn | 2.12 |
| 7 | Alnylam Pharmaceuticals | 35.14 Bn | 31.84 Bn | 992.69 Mn | 1.23 |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | 0.18 |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | -0.06 |
| 10 | Prelude Therapeutics | 536.22 Mn | 255.59 Mn | - | -0.16 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -0.16 |
| Mar 31, 2026 | -0.17 |
| Dec 31, 2025 | -0.23 |
| Sep 30, 2025 | -0.27 |
| Jun 30, 2025 | -0.42 |
| Mar 31, 2025 | -0.46 |
| Dec 31, 2024 | -0.45 |
| Sep 30, 2024 | -0.45 |
| Jun 30, 2024 | -0.49 |
| Mar 31, 2024 | -0.45 |
| Dec 31, 2023 | -0.62 |
| Sep 30, 2023 | -0.49 |
| Jun 30, 2023 | -0.58 |
| Mar 31, 2023 | -0.61 |
| Dec 31, 2022 | -0.70 |
| Sep 30, 2022 | -0.64 |
| Jun 30, 2022 | -0.62 |
| Mar 31, 2022 | -0.64 |
| Dec 31, 2021 | -0.72 |
| Sep 30, 2021 | -0.67 |